新冠感染后职业运动员心脏筛查中炎症性心脏病患病率
本研究汇总北美六大职业体育联盟789名新冠阳性运动员的返赛前心脏筛查数据,采用肌钙蛋白、心电图和静息超声心动图进行筛查。仅0.6%运动员最终发现提示炎症性心脏病的磁共振异常(心肌炎3例、心包炎2例),筛查后恢复参赛者未发生不良心脏事件。
要点
- 职业运动员新冠感染后炎症性心脏病检出率低(0.6%)。
- 系统返赛心脏筛查可安全支持恢复职业体育活动。
- 初始筛查异常者需进一步磁共振或负荷超声评估。
核心结论
- 在实施当前返赛心脏筛查建议下,新冠感染后职业运动员中相关炎症性心脏病患病率低,且筛查后恢复参赛未发生不良心脏事件。
研究设计与样本
- 横断面研究,纳入2020年5月至10月北美六大职业体育联盟中新冠检测阳性的789名职业运动员。
- 所有阳性运动员在恢复团队活动前接受强制心脏筛查(肌钙蛋白、心电图、静息超声心动图),异常者转诊额外检查。
主要发现
- 789名运动员平均年龄25(3)岁,777名(98.5%)为男性;460名(58.3%)有症状,329名(41.7%)无症状或轻微症状。
- 检测在阳性结果后平均19(17)天(范围3-156天)进行。
- 30名(3.8%)筛查异常:肌钙蛋白6名(0.8%)、心电图10名(1.3%)、超声心动图20名(2.5%)。
- 最终5名(0.6%)磁共振提示炎症性心脏病(心肌炎3例、心包炎2例),因此限制参赛。
- 接受筛查并恢复职业体育活动的运动员中未发生不良心脏事件。
关键数值与推荐
- 肌钙蛋白异常率0.8%(6/789),心电图异常率1.3%(10/789),超声心动图异常率2.5%(20/789)。
- 炎症性心脏病磁共振检出率0.6%(5/789),中心肌炎3例、心包炎2例。
临床怎么用
- 对新冠感染后职业运动员按推荐实施系统返赛心脏筛查(肌钙蛋白、心电图、超声心动图)。
- 筛查异常者应转诊进行心脏磁共振和/或负荷超声以明确炎症性心脏病。
- 筛查未见异常并恢复参赛的运动员短期内未发生不良心脏事件,支持安全返赛。
局限性
- 原文未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The major North American professional sports leagues were among the first to return to full-scale sport activity during the coronavirus disease 2019 (COVID-19) pandemic. Given the unknown incidence of adverse cardiac sequelae after COVID-19 infection in athletes, these leagues implemented a conservative return-to-play (RTP) cardiac testing program aligned with American College of Cardiology recommendations for all athletes testing positive for COVID-19. OBJECTIVE: To assess the prevalence of detectable inflammatory heart disease in professional athletes with prior COVID-19 infection, using current RTP screening recommendations. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study reviewed RTP cardiac testing performed between May and October 2020 on professional athletes who had tested positive for COVID-19. The professional sports leagues (Major League Soccer, Major League Baseball, National Hockey League, National Football League, and the men's and women's National Basketball Association) implemented mandatory cardiac screening requirements for all players who had tested positive for COVID-19 prior to resumption of team-organized sports activities. EXPOSURES: Troponin testing, electrocardiography (ECG), and resting echocardiography were performed after a positive COVID-19 test result. Interleague, deidentified cardiac data were pooled for collective analysis. Those with abnormal screening test results were referred for additional testing, including cardiac magnetic resonance imaging and/or stress echocardiography. MAIN OUTCOMES AND MEASURES: The prevalence of abnormal RTP test results potentially representing COVID-19-associated cardiac injury, and results and outcomes of additional testing generated by the initial screening process. RESULTS: The study included 789 professional athletes (mean [SD] age, 25 [3] years; 777 men [98.5%]). A total of 460 athletes (58.3%) had prior symptomatic COVID-19 illness, and 329 (41.7%) were asymptomatic or paucisymptomatic (minimally symptomatic). Testing was performed a mean (SD) of 19 (17) days (range, 3-156 days) after a positive test result. Abnormal screening results were identified in 30 athletes (3.8%; troponin, 6 athletes [0.8%]; ECG, 10 athletes [1.3%]; echocardiography, 20 athletes [2.5%]), necessitating additional testing; 5 athletes (0.6%) ultimately had cardiac magnetic resonance imaging findings suggesting inflammatory heart disease (myocarditis, 3; pericarditis, 2) that resulted in restriction from play. No adverse cardiac events occurred in athletes who underwent cardiac screening and resumed professional sport participation. CONCLUSIONS AND RELEVANCE: This study provides large-scale data assessing the prevalence of relevant COVID-19-associated cardiac pathology with implementation of current RTP screening recommendations. While long-term follow-up is ongoing, few cases of inflammatory heart disease have been detected, and a safe return to professional sports activity has thus far been achieved.
引用
- Martinez MW, Tucker AM, Bloom OJ, et al. Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening. JAMA Cardiol. 2021. PMID: 33662103. doi:10.1001/jamacardio.2021.0565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。